Glucocorticoid-induced hyperglycaemia in respiratory disease: a systematic review and meta-analysis by Breakey, S et al.
BR I E F R E POR T
Glucocorticoid-induced hyperglycaemia in respiratory disease:
a systematic review and meta-analysis
S. Breakey MB, BChir1 | S. J. Sharp PhD2 | A. I. Adler MD, PhD1 | B. G. Challis MRCP, PhD1
1Department of Medicine, Wolfson Diabetes
and Endocrine Clinic, Institute of Metabolic
Science, Addenbrooke’s Hospital,
Cambridge, UK
2MRC Epidemiology Unit, Institute of
Metabolic Science, University of Cambridge
School of Clinical Medicine, Cambridge, UK
Conflict of Interest: None declared.
Corresponding Authors: Dr Benjamin
G. Challis and Dr Amanda I. Adler, Wolfson
Diabetes and Endocrine Clinic, Institute of
Metabolic Science, Addenbrooke’s Hospital,
Cambridge, CB2 0QQ, UK (bc340@medschl.
cam.ac.uk; amanda.adler@addenbrookes.nhs.uk).
The relative risk of glucocorticoid-induced hyperglycaemia is poorly quantiﬁed. We undertook a
meta-analysis to estimate the association between glucocorticoid treatment and hyperglycaemia,
overall and separately in individuals with and without diabetes and underlying respiratory disease.
We searched electronic databases for clinical trials of adults randomized to either glucocorticoid
treatment or placebo. Eight articles comprising 2121 participants were identiﬁed. We performed a
random effects meta-analysis to determine relative risks for the associations between glucocorti-
coid use and both hyperglycaemia and starting hypoglycaemic therapy. In all individuals, the rela-
tive risk of hyperglycaemia comparing glucocorticoid treatment with placebo was 1.72 [95%
conﬁdence interval (CI) 1.50-2.04; p < .001]. The relative risks in individuals with and those with-
out diabetes were 2.10 (95% CI 0.92-5.02; p = .079) and 1.50 (95% CI 0.79-2.86; p = .22), respec-
tively. In all individuals, the relative risk of hyperglycaemia requiring initiation of hypoglycaemic
therapy, comparing glucocorticoid treatment with placebo, was 1.73 (95% CI 1.40-2.14; p < .001).
In conclusion, glucocorticoid therapy increases the risk of hyperglycaemia in all individuals with
underlying respiratory disease but not when diabetic status is analysed separately.
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1 | INTRODUCTION
Glucocorticoids are used to treat several diseases because of their
anti-inﬂammatory and immunosuppressive properties. In the UK, the
prevalence of glucocorticoid use at any one time is ~1%.1 Among
hospital inpatients, prevalence exceeds 10%, with most patients
receiving glucocorticoids to treat underlying respiratory illness.1 Glu-
cocorticoids are associated with well recognized metabolic complica-
tions, including hyperglycaemia. In patients with acute exacerbations
of chronic obstructive pulmonary disease (COPD) and community-
acquired pneumonia, hyperglycaemia is associated with prolonged
hospital admissions and mortality.2
Current data regarding glucocorticoid-induced hyperglycaemia
are based on data from retrospective prescription databases3 or pro-
spective studies, which vary in glucocorticoid type, dose, treatment
regime, administration route and underlying disease.4 These studies
show that glucocorticoids worsen hyperglycaemia in people with
known diabetes; however, the magnitude of this risk, and the risk of
developing hyperglycaemia after glucocorticoid exposure in people
without diabetes, is not clear.
Using meta-analytical techniques, the present study estimates
the relative risk of glucocorticoid treatment and hyperglycaemia in
individuals with and without diabetes and underlying respiratory dis-
ease. It also estimates the association between glucocorticoid use
and initiation of hypoglycaemic therapy.
2 | RESEARCH DESIGN AND METHODS
2.1 | Literature search
We searched the electronic databases MEDLINE, EMBASE, Cochrane
and ClinicalTrials.gov. We searched MEDLINE using standard medical
subject heading (MeSH) terms (“glucocorticoids,” “pneumonia,” “pul-
monary disease,” “diabetes mellitus” and “community-acquired infec-
tion”) and free text (“respiratory,” “hyperglycaemia,” “steroid” and
“prednisolone”) terms. We searched EMBASE using “map term to
subject heading” in Advanced Ovid Search. We scanned reference
lists of relevant articles to supplement our literature search. We did
not restrict the date of study publication.
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2.2 | Study selection
We identiﬁed citations in MEDLINE (n = 262), EMBASE (n = 1475),
Cochrane Database (n = 138) and ClinicalTrials.gov (n = 112), plus
48 additional citations obtained through scanning reference lists. We
included studies with patients aged ≥18 years not treated at baseline
with systemic (including inhaled) glucocorticoids for underlying
COPD, pneumonia or interstitial lung disease. We included trials if
participants received orally or intravenously administered glucocorti-
coids (≥5 mg prednisolone equivalent) or placebo and/or additional
therapy for underlying pulmonary disease for at least 72 hours. We
included studies that documented glycaemia throughout, including
diabetic status at baseline, and that documented when therapy for
hyperglycaemia started. Our primary outcome was hyperglycaemia,
as deﬁned by each study-speciﬁc protocol. Our secondary outcome
was hyperglycaemia requiring therapy. Eight studies, comprising 2121
participants, met our inclusion criteria (Supplementary Figure S1).
2.3 | Data abstraction
We collected the following data from each study: study design; year
of publication; number of participants; age; sex; underlying respira-
tory disease; diabetes status at study entry; type and dose of gluco-
corticoid; method and frequency of quantifying blood glucose; new
hyperglycaemia; new hypoglycaemic therapy in response to hypergly-
caemia; type of hypoglycaemic agent; and length of follow-up. Where
published data were not available, we communicated with investiga-
tors of included studies to obtain additional data about the diabetic
status of participants.
2.4 | Statistical analysis
We calculated a pooled estimate of the association between gluco-
corticoid treatment and hyperglycaemia by combining the study-
speciﬁc relative risks and absolute risk difference using random
effects meta-analysis. We assessed heterogeneity between studies
using the I2-statistic. To investigate small study effects, we used
Begg’s funnel plot.
3 | RESULTS
3.1 | Description of studies
Supplementary Table S1 displays the details of the trial characteristics,
all of which were placebo-controlled.5–12 The primary endpoints of the
trials were respiratory measures rather than hyperglycaemia. All trials
were double-blind with the exception of one open-label study.6 The
proportion of participants with pre-existing diabetes at study entry
was provided in seven studies and ranged from 10.3% to 28.9%.
3.2 | Relative risk of hyperglycaemia after
glucocorticoid treatment in all individuals
Based on eight studies, the relative risk of any hyperglycaemia, com-
paring glucocorticoid treatment with placebo, was 1.72 [95%
conﬁdence interval (CI) 1.50-2.04; p < .001; I2 = 0% (Figure 1A)]. The
funnel plot suggests publication bias, with smaller, less precise studies
reporting positive associations (Supplementary Figure S2). The
number-needed-to-treat for an additional harmful outcome (NNTH)
was calculated for the primary outcome. For baseline risks of 5% and
15%, the NNTH was 28 (95% CI 19-43) and 9 (95% CI 6-14),
respectively.
3.3 | Relative risk of hyperglycaemia requiring
initiation of new hypoglycaemic therapy after
glucocorticoid treatment in all individuals
Seven studies reported the association between glucocorticoids and
hyperglycaemia requiring initiation of new hypoglycaemic therapy.
The relative risk, comparing glucocorticoid treatment with placebo,
was 1.70 [95% CI 1.40-2.14; p < .001, I2 = 0% (Figure 1B)]. The fun-
nel plot suggests evidence of publication bias (Supplementary
Figure S3).
3.4 | Relative risk of hyperglycaemia after
glucocorticoid treatment in individuals without
known diabetes
Three studies reported the association between glucocorticoid treat-
ment and hyperglycaemia in individuals without known diabe-
tes.8,10,12 The relative risk, comparing glucocorticoid treatment with
placebo, was 1.50 [95% CI 0.79-2.86; p = .22, I2 = 29% (Figure 2A)].
3.5 | Relative risk of hyperglycaemia after
glucocorticoid treatment in individuals with known
diabetes
Three studies reported the association between glucocorticoid treat-
ment and hyperglycaemia in individuals with known diabetes.8,10,12
The relative risk, comparing glucocorticoid treatment with placebo,
was 2.10 (95% CI 0.92-5.02; p = .079, I2 = 68% (Figure 2B)].
4 | DISCUSSION
The ﬁndings of this meta-analysis show that trial participants rando-
mized to glucocorticoid treatment are more likely to develop hyper-
glycaemia than those randomized to placebo. We found no evidence
of a signiﬁcantly increased risk of hyperglycaemia for individuals ana-
lysed based on diabetic status who were randomized to glucocorti-
coid treatment.
The risk increase we report depends on the deﬁnition of hyper-
glycaemia in the trials. Six of eight studies did not provide a deﬁnition
of hyperglycaemia. In one study, hyperglycaemia was deﬁned as
plasma blood glucose concentration ≥180 mg/dL (10 mmol/L),6
whereas a second study deﬁned hyperglycaemia as glucose concen-
trations ≥120 mg/dL (6.7 mmol/L).8 Despite these differences, we
found little important heterogeneity between studies. By limiting our
analyses to randomized clinical trials, we have minimized the possibil-
ity that the patients most likely to develop hyperglycaemia were also
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those most likely to receive glucocorticoids; however, we cannot
exclude the possibility that detection bias occurred. For example,
patients randomized to glucocorticoids may have experienced other
glucocorticoid-related adverse effects which caused them to seek
medical care where clinicians documented hyperglycaemia. We are
also aware, however, that patients randomized to placebo may have
been more likely than patients randomized to glucocorticoids to seek
medical attention for their underlying respiratory disease; therefore,
it is unclear in which direction this potential bias might inﬂuence the
estimates we report.
A Cochrane review systematically assessed the risk of hypergly-
caemia in six studies that administered glucocorticoids to treat acute
exacerbations of COPD; however, diabetic status was not ascer-
tained.13 Of the studies included, one relied on glycosuria as the
measure of glycaemic control, which is not current standard of care.
Another study did not include glucose monitoring as part of the study
protocol, and therefore may have missed hyperglycaemia. Our
estimate is lower (1.72) than the odds ratio (2.8) reported in the
Cochrane review estimating the association between glucocorticoid
use and hyperglycaemia in a population comprising people with and
without diabetes.
Observational studies have estimated odds ratios ranging
between 1.36 and 2.31 for the association between glucocorticoid
therapy and new-onset diabetes mellitus; however, the primary end-
points for these studies were new prescriptions ﬁlled for glucocorti-
coids3 or hypoglycaemic agents14 rather than biochemical
assessment of glycaemia. A meta-analysis found that 19% of
patients without diabetes developed glucocorticoid-induced hyper-
glycaemia after glucocorticoid treatment4; however, the study did
not report hyperglycaemia risk in patients with diabetes not treated
with glucocorticoids. Moreover, the majority of studies analysed in
the meta-analysis were retrospective, combined a wide range of
patient populations and disease states, and, as did our study, identi-
ﬁed publication bias.
Study
Niewoehner 1999
Maltais 2002
Snijders 2010
Meijvis 2011
Alia 2011
Abroug 2014
Blum 2015
Torres 2015
Summary
Events/Total 
(Control group)
4/111
0/66
2/109
35/153
10/40
35/106
59/393
7/59
Events/Total 
(Steroid group)
24/160
7/62
5/104
67/151
20/43
55/111
93/392
11/61
Relative Risk 
(95% CI)
4.16 (1.49,11.7)
14.9 (0.85,262.4)
2.62 (0.52,13.2)
1.94 (1.38,2.73)
1.86 (1.00,3.48)
1.50 (1.08,2.09)
1.58 (1.19,2.13)
1.52 (0.63,3.66)
1.72 (1.46,2.04)
0.50 1.0 2.0 5.0
Relative Risk (95% CI)
Study
Niewoehner 1999
Maltais 2002
Snijders 2010
Meijvis 2011
Alia 2011
Abroug 2014
Blum 2015
Summary
Events/Total 
(Control group)
4/111
0/66
2/109
5/153
10/40
35/106
43/393
Events/Total 
(Steroid group)
24/160
2/62
5/104
7/151
20/43
55/111
76/392
Relative Risk 
(95% CI)
4.16 (1.49,11.7)
4.26 (0.19,94.4)
2.62 (0.52,13.2)
1.42 (0.46,4.37)
1.86 (1.00,3.48)
1.50 (1.08,2.09)
1.77 (1.25,2.51)
1.73 (1.40,2.14)
0.50 1.0 2.0 5.0
Relative Risk (95% CI)
A
B
FIGURE 1 (A) Relative risk of
hyperglycaemia, comparing
glucocorticoid treatment with
placebo in all individuals. (B)
Relative risk of hyperglycaemia
requiring initiation of
hypoglycaemic therapy,
comparing glucocorticoid
treatment with placebo in all
individuals.
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Glucocorticoids increase hepatic gluconeogenesis, reduce periph-
eral glucose uptake, inhibit insulin secretion and cause postprandial
hyperglycaemia. Seven studies included in the present analysis did
not deﬁne the timing of blood glucose measurements. One study, in
which patients were randomized to once-daily intravenous dexa-
methasone or placebo, sampled blood daily at 08:00 hours, which
may not be sensitive to hyperglycaemia10 and may have biased the
effect measure we report. It has been shown that glucocorticoids
administered in the morning increase the value of blood glucose into
the evening, peaking 8 hours later, diminishing overnight, and result-
ing in normal fasting glucose levels the following morning.15
In summary, the data suggest that glucocorticoids increase the
risk of hyperglycaemia in patients with respiratory disease. In subjects
analysed based on diabetic status alone, if an association between
treatment with glucocorticoids and hyperglycaemia exists, then this
study did not ﬁnd it. Our estimates may reﬂect publication bias. We
recommend that future trials of glucocorticoids determine glycaemia
at baseline, during follow-up, and at time intervals that reﬂect the
pharmacokinetic actions of glucocorticoids.
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